AA
AARD.US Aardvark Therapeutics, Inc. Common Stock
- Market cap
- USD 33.3M
- P/E
- -
- P/B
- 0.47x
- ROE
- -96.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AARD.US undervalued?
Graham numberThe Graham number of Aardvark Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aardvark Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Aardvark Therapeutics, Inc. Common Stock yet.
Aardvark Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Full company profileAardvark Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aardvark Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -110K | -97.0K | -16.0K | -36.0K | - |
| Operating Income | -11.4M | -7.42M | -22.8M | -62.7M | -75.1M |
| EBITDA | -10.8M | -6.56M | -22.7M | -57.6M | -71.9M |
| Net Income | -13.6M | -7.21M | -20.6M | -57.6M | -72.0M |
| EPS | -0.63 | -0.34 | -0.95 | -2.64 | -3.29 |
| Balance Sheet | |||||
| Total Assets | 16.8M | 10.5M | 77.5M | 117M | 81.5M |
| Total Liabilities | 44.7M | 45.3M | 132M | 10.5M | 6.66M |
| Shareholders' Equity | -27.9M | -34.8M | -54.6M | 107M | 74.8M |
| Cash & Short-term Investments | 16.1M | 9.99M | 73.7M | 110M | 73.9M |
| Total Debt | 262K | 162K | 779K | 441K | 677K |
| Cash Flow | |||||
| Operating Cash Flow | -10.5M | -5.82M | -18.1M | -54.2M | -72.9M |
| Capital Expenditure | 0.00 | 0.00 | 109K | 95.0K | 0.00 |
| Free Cash Flow | -10.5M | -5.82M | -18.2M | -54.3M | -72.9M |
| Ratios | |||||
| ROE | - | - | - | -54.0% | -96.2% |
| ROA | -80.9% | -68.4% | -26.6% | -49.1% | -88.3% |
| Debt to Equity | - | - | - | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aardvark Therapeutics, Inc. Common Stock dividends
Aardvark Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Aardvark Therapeutics, Inc. Common Stock
- Insiders 15.77%
- Institutions 52.45%
- Public & others 31.78%
- Shares outstanding 21.9M
- Free float 11.0M
Top funds holding AARD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 409K | 1.87% | 0.00% | Sep 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 400K | 1.83% | +110.53% | Oct 2026 |
| iShares Biotechnology ETF | 98.3K | 0.45% | -0.19% | Oct 2026 |
| Fidelity Extended Market Index | 67.2K | 0.31% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 38.4K | 0.18% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 23.4K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 22.6K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 18.7K | 0.09% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 17.1K | 0.08% | +0.20% | Oct 2026 |
| Vanguard Balanced Index Inv | 8.87K | 0.04% | 0.00% | Sep 2026 |
| Fidelity VIP Disciplined Small Cap Init | 7.98K | 0.04% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 5.89K | 0.03% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 4.87K | 0.02% | 0.00% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 3.47K | 0.02% | -2.14% | Jun 2026 |
| Dimensional Global Core Equity USD Acc | 3.17K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 2.77K | 0.01% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 2.24K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 2.09K | 0.01% | 0.00% | Sep 2026 |
| Invesco Nasdaq Biotechnology ETF | 1.66K | 0.01% | 0.00% | Oct 2026 |
| AQR Small Cap Multi-Style I | 1.50K | 0.01% | 0.00% | Jun 2026 |
Top institutions holding AARD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Decheng Capital LLC | 3.92M | 17.90% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.28M | 5.86% | +3.25% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 1.03M | 4.73% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 563K | 2.57% | +1.58% | Jun 2026 |
| AQR Capital Management LLC | 480K | 2.19% | +257.08% | Jun 2026 |
| EcoR1 Capital, LLC | 396K | 1.81% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 300K | 1.37% | 0.00% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 233K | 1.07% | +249.67% | Jun 2026 |
| BlackRock Inc | 187K | 0.85% | -76.40% | Jun 2026 |
| Geode Capital Management, LLC | 150K | 0.68% | -51.58% | Jun 2026 |
| Two Sigma Investments LLC | 108K | 0.50% | -33.66% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 75.2K | 0.34% | -9.66% | Jun 2026 |
| Woodline Partners LP | 72.4K | 0.33% | 0.00% | Jun 2026 |
| Millennium Management LLC | 69.9K | 0.32% | -28.87% | Jun 2026 |
| State Street Corp | 59.3K | 0.27% | -70.26% | Jun 2026 |
| J. Goldman & Co LP | 40.5K | 0.19% | 0.00% | Jun 2026 |
| IEQ CAPITAL, LLC | 38.4K | 0.18% | +132.83% | Jun 2026 |
| UBS Group AG | 35.6K | 0.16% | -77.43% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 30.2K | 0.14% | +71.83% | Jun 2026 |
| Northern Trust Corp | 28.1K | 0.13% | -68.31% | Jun 2026 |
Aardvark Therapeutics, Inc. Common Stock company profile
- Company name
- Aardvark Therapeutics, Inc. Common Stock
- Ticker
- AARD.US
- Exchange
- USA Stocks
- Listed since
- Feb 13, 2025
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 28
- Fiscal year end
- December
- Address
- 4370 La Jolla Village Drive, San Diego, CA, United States, 92122
- Phone
- 858 225 7696
- Website
- aardvarktherapeutics.com
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Aardvark Therapeutics, Inc. Common Stock management
10- Dr. Tien-Li Lee M.D.CEO, Secretary & Chairman · born 1975
- Mr. Nelson B. Sun M.B.A.CFO & COO · born 1977
- Dr. Manasi Sinha Jaiman M.D., M.P.H.Chief Medical Officer · born 1981
- Dr. Dvorit Samid Ph.D.Executive Vice President of Medical Affairs
- Dr. Zhenhuan Zheng Ph.D.Chief Research Officer
- Mr. Ron Lewis II, Ph.D.VP & Head of CMC
- Mr. Justin T. Stege Ph.D.VP and Head of Project Management & Strategy
- Mr. Derrick C. LiChief Business Officer
- Dr. Christopher J. Kemmerer Ph.D.Executive Vice President of Technical Operations · born 1964
- Dr. Bryan Jones Ph.D.Chief Executive Officer of Ardia · born 1964